Immune globulin - LFB Biotechnologies

Drug Profile

Immune globulin - LFB Biotechnologies

Alternative Names: Clairyg; I10E; Immunoglobulin liquid intravenous - LFB Biotechnologies; Iqymune

Latest Information Update: 13 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LFB Biotechnologies
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Autoimmune disorders; Immunodeficiency disorders
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease

Most Recent Events

  • 01 Jul 2016 LFB Biotechnologies completes a phase III trial in Motor Neuron Disease in France, Italy, Spain and United Kingdom (NCT01951924)
  • 30 Mar 2015 LFB Biotechnologies initiates the phase III PRISM I trial in Chronic inflammatory demyelinating polyradiculoneuropathy in United Kingdom (UKCRN17067)
  • 11 Dec 2014 LFB Biotechnologies plans the phase III PRISM2 trial for Chronic inflammatory demyelinating polyradiculoneuropathy in France, Italy, Spain and the UK (NCT02317562)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top